Sath Shukla, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 6,017 shares at $1.30 ($8K) on 2023-08-29, disclosed to the SEC on 2023-08-30.
Scheduled sale ($8k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.26 | 1,854 | $2K | 30.2% |
| 2 | $1.30 | 4,163 | $5K | 69.8% |
| Total | $1.29 avg | 6,017 | $8K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-06 | $43K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $173K | — | Filing → |
| SPRO | SELL | 2023-02-03 | $17K | — | Filing → |